Developmental Clinical Studies - Gene Therapy For Vein Graft Failure

Around half of heart bypass grafts using leg veins fail within a decade because the veins become blocked—a problem no existing drug can prevent. This trial tests whether gene therapy can stop that blockage. The researchers will take a patient’s own genes and deliver them directly into the vein wall during bypass surgery. Earlier lab work showed that this genetic intervention can keep the graft open by preventing the abnormal cell growth that narrows the vessel. The current study moves that finding into patients, assessing both safety and whether the treatment actually works. If successful, gene therapy could become a routine addition to bypass surgery, saving tens of thousands of patients each year from repeat operations, chest pain, or heart attacks. It would also open a new route for treating other types of graft failure—for example in dialysis access or peripheral artery disease—where blocked vessels are a persistent problem. The research is a direct clinical translation of fundamental discoveries in vascular biology and gene delivery, not a curiosity-driven exploration. Its impact, if positive, would be felt in operating theatres and cardiac wards within a few years.